biostudies-literatureChen JNational Natural Science Foundation of ChinaJinling HospitalKey R and D Program in Jiangsu Province17588359231225036https://www.ebi.ac.uk/biostudies/studies/S-EPMC10901068biostudies-literatureUnknown16<h4>Background</h4>Immunotherapy is an emerging antitumor therapy that can improve the survival of patients with advanced non-small-cell lung cancer (NSCLC). However, only about 20% of NSCLC patients can benefit from this treatment. At present, whether patients with driving gene-positive NSCLC can benefit from immunotherapy is one of the hot issues. Therefore, we conducted a meta-analysis to evaluate the efficacy of immunotherapy in patients with oncogene-driven NSCLC and concluded the efficacy of altered subtypes.<h4>Methods</h4>A literature search was performed using PubMed, Web of Science, and Cochrane databases. The primary endpoints included the objective response rate (ORR), median progression-free survival (mPFS), and median overall survival (mOS) in patients with oncogene-driven NSTherapeutic advances in medical oncologyEfficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: a systematic review and meta-analysis.PMC1090106882002456YYZD2021008BE2019719YYQN2021085Zhan PLiu XYe MLv JLu WChen JChen MWang DCai ZLv TZhu SSong YfalseEfficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: a systematic review and meta-analysis.<h4>Background</h4>Immunotherapy is an emerging antitumor therapy that can improve the survival of patients with advanced non-small-cell lung cancer (NSCLC). However, only about 20% of NSCLC patients can benefit from this treatment. At present, whether patients with driving gene-positive NSCLC can benefit from immunotherapy is one of the hot issues. Therefore, we conducted a meta-analysis to evaluate the efficacy of immunotherapy in patients with oncogene-driven NSCLC and concluded the efficacy of altered subtypes.<h4>Methods</h4>A literature search was performed using PubMed, Web of Science, and Cochrane databases. The primary endpoints included the objective response rate (ORR), median progression-free survival (mPFS), and median overall survival (mOS) in patients with oncogene-driven NS2024-01-01T00:00:00Z20242025-04-22T06:39:19.743Z2025-04-05T21:48:47.818ZS-EPMC109010683842060210.1177/17588359231225036